Sector Alpha Week of 2026-08-04
20-quarter listed-company comparison

Health Information Services Stocks

Health Information Services: Veeva Systems Inc. owns the largest revenue base; Carlsmed, Inc. has the fastest current growth.

01 · the industry itself · before any single company

How has Health Information Services moved against S&P 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this industry is 7% ahead of S&P 500. Earnings across its companies grew 11% on average over the last four reported quarters. It has been ahead of S&P 500 on a rolling three-month view for 14 weeks running.

FADING · −7 in 4w~Moving with the index16 of 28 companies ahead of S&P 500 by 5% or more over three months1 is 20% or more behind over a year while earnings grew 20% or more

RS ↑14w · 18/28 >200d (+0) · 16/28 lead (−7) · EPS 17/28↑

10020020262025202420232022 190348 TRAILING 12-MONTH EPS · 100 AT THE START0100101Mar 22Sep 22Mar 23Sep 23Mar 24Sep 24Mar 25Sep 25Mar 26Mar 2022 · trailing 12-month earnings per share at 100, against 100 at the start · no comparable year yet · 7 reportingJun 2022 · trailing 12-month earnings per share at 101, against 100 at the start · no comparable year yet · 8 reportingSep 2022 · trailing 12-month earnings per share at 95, against 100 at the start · no comparable year yet · 8 reportingDec 2022 · trailing 12-month earnings per share at 84, against 100 at the start · no comparable year yet · 8 reportingMar 2023 · trailing 12-month earnings per share at 79, against 100 at the start · down 38.1% on a year ago · 8 reportingJun 2023 · trailing 12-month earnings per share at 80, against 100 at the start · down 21.4% on a year ago · 8 reportingSep 2023 · trailing 12-month earnings per share at 82, against 100 at the start · down 19.7% on a year ago · 8 reportingDec 2023 · trailing 12-month earnings per share at 90, against 100 at the start · down 1.6% on a year ago · 8 reportingMar 2024 · trailing 12-month earnings per share at 90, against 100 at the start · up 3.2% on a year ago · 8 reportingJun 2024 · trailing 12-month earnings per share at 85, against 100 at the start · down 55.6% on a year ago · 8 reportingSep 2024 · trailing 12-month earnings per share at 83, against 100 at the start · down 1.3% on a year ago · 8 reportingDec 2024 · trailing 12-month earnings per share at 72, against 100 at the start · down 3.9% on a year ago · 8 reportingMar 2025 · trailing 12-month earnings per share at 67, against 100 at the start · up 1.3% on a year ago · 8 reportingJun 2025 · trailing 12-month earnings per share at 43, against 100 at the start · up 10.7% on a year ago · 8 reportingSep 2025 · trailing 12-month earnings per share at 72, against 100 at the start · up 19.7% on a year ago · 8 reportingDec 2025 · trailing 12-month earnings per share at 95, against 100 at the start · up 20.0% on a year ago · 8 reportingMar 2026 · trailing 12-month earnings per share at 87, against 100 at the start · down 7.6% on a year ago · 8 reportingNot reported yet — earnings trail price by a quarter or two87 · Mar 26No earnings on file this far back — the price series reaches further than the filings do
10020020262025202420232022 190348 TRAILING 12-MONTH EPS · 100 AT THE START0100101Mar 22Mar 23Mar 24Mar 25Mar 26Mar 2022 · trailing 12-month earnings per share at 100, against 100 at the start · no comparable year yet · 7 reportingJun 2022 · trailing 12-month earnings per share at 101, against 100 at the start · no comparable year yet · 8 reportingSep 2022 · trailing 12-month earnings per share at 95, against 100 at the start · no comparable year yet · 8 reportingDec 2022 · trailing 12-month earnings per share at 84, against 100 at the start · no comparable year yet · 8 reportingMar 2023 · trailing 12-month earnings per share at 79, against 100 at the start · down 38.1% on a year ago · 8 reportingJun 2023 · trailing 12-month earnings per share at 80, against 100 at the start · down 21.4% on a year ago · 8 reportingSep 2023 · trailing 12-month earnings per share at 82, against 100 at the start · down 19.7% on a year ago · 8 reportingDec 2023 · trailing 12-month earnings per share at 90, against 100 at the start · down 1.6% on a year ago · 8 reportingMar 2024 · trailing 12-month earnings per share at 90, against 100 at the start · up 3.2% on a year ago · 8 reportingJun 2024 · trailing 12-month earnings per share at 85, against 100 at the start · down 55.6% on a year ago · 8 reportingSep 2024 · trailing 12-month earnings per share at 83, against 100 at the start · down 1.3% on a year ago · 8 reportingDec 2024 · trailing 12-month earnings per share at 72, against 100 at the start · down 3.9% on a year ago · 8 reportingMar 2025 · trailing 12-month earnings per share at 67, against 100 at the start · up 1.3% on a year ago · 8 reportingJun 2025 · trailing 12-month earnings per share at 43, against 100 at the start · up 10.7% on a year ago · 8 reportingSep 2025 · trailing 12-month earnings per share at 72, against 100 at the start · up 19.7% on a year ago · 8 reportingDec 2025 · trailing 12-month earnings per share at 95, against 100 at the start · up 20.0% on a year ago · 8 reportingMar 2026 · trailing 12-month earnings per share at 87, against 100 at the start · down 7.6% on a year ago · 8 reportingNot reported yet — earnings trail price by a quarter or two87No earnings on file this far back — the price series reaches further than the filings do
Health Information Services, equal-weighted, based at 200 S&P 500, same base, same start trailing 12-month earnings per share rising falling

Both lines start at 200 in the same week, so the distance between them is the whole story: the industry line is an equal-weighted index of its 28 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the industry taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.

02 · sector relative strength, before individual stocks

Is Health Information Services outperforming S&P 500?

Health Information Services has underperformed S&P 500 by 9.3% over the last 52 weeks. Over 13 weeks the gap is a lead of 8.3%. 12 of 29 covered companies currently beat the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. 10x Genomics, Inc. is the strongest against the sector itself at +91.7%.

+8.3%Sector vs S&P 500 · 13 weeks
-9.3%Sector vs S&P 500 · 52 weeks
12/29Stocks leading S&P 500
12/29Stocks leading sector

Sector metric: — as of latest available · unclassified · direction unavailable.

The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.

Bottom line

Health Information Services has underperformed S&P 500 by 9.3% over 52 weeks and 8.3% over 13 weeks. 12 of 29 covered companies beat the S&P 500 on Mansfield relative strength, while 12 of 29 beat the sector itself. Veeva Systems Inc. leads with revenue of $3,319 million, based on 22 of 29 comparable companies through Jun 2026.

Companies
29
complete canonical membership
Combined market value
$104.8B
Veeva Systems Inc.
Revenue growing
18/22
positive TTM year-on-year growth
Beating S&P 500
12/29
positive Mansfield relative strength
Comparing 5 of 29
03 · research priority, made explicit

4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
HealthEquity, Inc. has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 85.3% evidence confidence.
SOPHiA GENETICS SA has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.
How this score is built, and what the marks mean

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1HealthEquity, Inc.HQY 67.9/100Favorable setup85% evidence BREAKING OUT 23.6/35 Revenue 7.6% · PAT 89.3% · OPM change 3.9 pp 95% evidence 15.5/25 ROCE 3.2% · OPM 29% 76% evidence 12.4/20 P/E 30.7× · PEG 1.57 65% evidence 16.4/20 RS sector 4.3% · RS bench 5.3% · 1Y 12.8%5 of 12 weeks ahead 100% evidence
Exact sum: 23.6 + 15.5 + 12.4 + 16.4 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Simulations Plus, Inc.SLP 64.2/100Thin evidence · provisional52% evidence LEADER 24.6/35 Revenue — · PAT — · OPM change 11.1 pp 45% evidence 16.2/25 ROCE 3.4% · OPM 23.2% 76% evidence 10.3/20 P/E 42.8× · PEG — 15% evidence 13.1/20 RS sector 2.4% · RS bench 3.2% · 1Y 29.5%12 of 12 weeks ahead 70% evidence
Exact sum: 24.6 + 16.2 + 10.3 + 13.1 = 64.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
3Hinge Health, Inc.HNGE 61.7/100Mixed-positive evidence62% evidence LEADER 19.9/35 Revenue 49.5% · PAT -1748.4% · OPM change 7 pp 83% evidence 15.1/25 ROCE 8.4% · OPM 17.6% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 16.7/20 RS sector 35% · RS bench 35.8% · 1Y 40.1%12 of 12 weeks ahead 70% evidence
Exact sum: 19.9 + 15.1 + 10 + 16.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Veeva Systems Inc.VEEV 61.5/100Mixed-positive evidence85% evidence BREAKING OUT 20.5/35 Revenue 16.3% · PAT 20.5% · OPM change 0.1 pp 95% evidence 17.7/25 ROCE 4% · OPM 30.9% 76% evidence 13.8/20 P/E 27.8× · PEG 1.47 65% evidence 9.5/20 RS sector -12.6% · RS bench -13% · 1Y -24.9%5 of 12 weeks ahead 100% evidence
Exact sum: 20.5 + 17.7 + 13.8 + 9.5 = 61.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
510x Genomics, Inc.TXG 56.9/100Mixed-positive evidence61% evidence LEADER 20.1/35 Revenue 2.2% · PAT — · OPM change 14.1 pp 62% evidence 6.8/25 ROCE -2% · OPM -11.3% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 20.0/20 RS sector 91.7% · RS bench 96.6% · 1Y 289.4%12 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 6.8 + 10 + 20 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6BrightSpring Health Services, Inc.BTSG 56.2/100Thin evidence · provisional58% evidence LEADER 19.7/35 Revenue — · PAT — · OPM change 1.6 pp 45% evidence 12.7/25 ROCE 2.9% · OPM 3.4% 76% evidence 10.1/20 P/E 44.4× · PEG — 15% evidence 13.7/20 RS sector 27.5% · RS bench 31.3% · 1Y 202.1%12 of 12 weeks ahead 100% evidence
Exact sum: 19.7 + 12.7 + 10.1 + 13.7 = 56.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7HealthStream, Inc.HSTM 55.8/100Mixed-positive evidence81% evidence BREAKING OUT 19.0/35 Revenue 6.5% · PAT 5.3% · OPM change 3.3 pp 83% evidence 14.2/25 ROCE 1.9% · OPM 9.3% 76% evidence 5.6/20 P/E 30.9× · PEG 4.87 65% evidence 17.0/20 RS sector 8.6% · RS bench 9.2% · 1Y 14.7%11 of 12 weeks ahead 100% evidence
Exact sum: 19 + 14.2 + 5.6 + 17 = 55.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8Omada Health, Inc.OMDA 53.6/100Thin evidence · provisional55% evidence BREAKING OUT 25.2/35 Revenue 49% · PAT — · OPM change 9.2 pp 62% evidence 7.0/25 ROCE -2.9% · OPM -6.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 11.4/20 RS sector 1.2% · RS bench 0.6% · 1Y 6.1%12 of 12 weeks ahead 70% evidence
Exact sum: 25.2 + 7 + 10 + 11.4 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
9Phreesia, Inc.PHR 49.2/100Mixed-negative evidence67% evidence BREAKING OUT 22.7/35 Revenue 13.8% · PAT 100% · OPM change 8 pp 71% evidence 10.9/25 ROCE 1.7% · OPM 5.2% 76% evidence 9.7/20 P/E 61.4× · PEG — 15% evidence 5.9/20 RS sector -34.4% · RS bench -35.7% · 1Y -57.6%5 of 12 weeks ahead 100% evidence
Exact sum: 22.7 + 10.9 + 9.7 + 5.9 = 49.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10Omnicell, Inc.OMCL 47.3/100Thin evidence · provisional58% evidence ASLEEP 21.4/35 Revenue — · PAT — · OPM change 9.7 pp 45% evidence 12.8/25 ROCE 2.1% · OPM 5.4% 76% evidence 9.9/20 P/E 49.4× · PEG — 15% evidence 3.2/20 RS sector -15.2% · RS bench -13.5% · 1Y 20.5%5 of 12 weeks ahead 100% evidence
Exact sum: 21.4 + 12.8 + 9.9 + 3.2 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
11SOPHiA GENETICS SASOPH 47.0/100Thin evidence · provisional55% evidence BREAKING OUT 17.4/35 Revenue 19.1% · PAT — · OPM change 10.5 pp 62% evidence 3.6/25 ROCE -15.1% · OPM -79.7% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 16.0/20 RS sector 26.6% · RS bench 29.3% · 1Y 115.1%6 of 12 weeks ahead 70% evidence
Exact sum: 17.4 + 3.6 + 10 + 16 = 47 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12Weave Communications, Inc.WEAV 46.5/100Thin evidence · provisional55% evidence BREAKING OUT 21.7/35 Revenue 16.4% · PAT — · OPM change 7.5 pp 62% evidence 5.6/25 ROCE -5.1% · OPM -9.2% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 9.2/20 RS sector -2.5% · RS bench -2.2% · 1Y -9.2%8 of 12 weeks ahead 70% evidence
Exact sum: 21.7 + 5.6 + 10 + 9.2 = 46.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13Waystar Holding Corp.WAY 46.1/100Thin evidence · provisional58% evidence TURNING 16.6/35 Revenue — · PAT — · OPM change 0.2 pp 45% evidence 12.6/25 ROCE 1.5% · OPM 25.6% 76% evidence 11.0/20 P/E 29.3× · PEG — 15% evidence 5.9/20 RS sector -25.5% · RS bench -25.7% · 1Y -31.3%1 of 12 weeks ahead 100% evidence
Exact sum: 16.6 + 12.6 + 11 + 5.9 = 46.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14NRC HealthNRC 45.7/100Thin evidence · provisional52% evidence FADING 12.6/35 Revenue — · PAT — · OPM change -9.6 pp 45% evidence 11.5/25 ROCE -3.1% · OPM 16% 76% evidence 9.0/20 P/E 86.3× · PEG — 15% evidence 12.6/20 RS sector 1.5% · RS bench 3.4% · 1Y 29.7%9 of 12 weeks ahead 70% evidence
Exact sum: 12.6 + 11.5 + 9 + 12.6 = 45.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
15TruBridge, Inc.TBRG 45.3/100Thin evidence · provisional58% evidence 10.9/35 Revenue 0% · PAT — · OPM change -5.9 pp 62% evidence 10.0/25 ROCE 0.9% · OPM 3.5% 76% evidence 9.2/20 P/E 73.2× · PEG — 15% evidence 15.2/20 RS sector 5.2% · RS bench 11% · 1Y 18.9%8 of 8 weeks ahead to 2026-07-10 70% evidence
Exact sum: 10.9 + 10 + 9.2 + 15.2 = 45.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16Carlsmed, Inc.CARL 45.2/100Thin evidence · provisional55% evidence BREAKING OUT 21.3/35 Revenue 75% · PAT — · OPM change -1.5 pp 62% evidence 4.2/25 ROCE -11.7% · OPM -57.6% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 9.7/20 RS sector -2.3% · RS bench -1.5% · 1Y 5.6%4 of 12 weeks ahead 70% evidence
Exact sum: 21.3 + 4.2 + 10 + 9.7 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17Privia Health Group, Inc.PRVA 44.2/100Mixed-negative evidence81% evidence ASLEEP 22.8/35 Revenue 24.7% · PAT 40% · OPM change 0.1 pp 83% evidence 11.1/25 ROCE 1% · OPM 1.2% 76% evidence 4.7/20 P/E 128.6× · PEG 3.86 65% evidence 5.6/20 RS sector -10.3% · RS bench -9.2% · 1Y 15.6%4 of 12 weeks ahead 100% evidence
Exact sum: 22.8 + 11.1 + 4.7 + 5.6 = 44.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.3% and the one-year return is 15.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
18GoodRx Holdings, Inc.GDRX 42.2/100Mixed-negative evidence65% evidence BREAKING OUT 8.6/35 Revenue -1.3% · PAT -31% · OPM change -4.3 pp 83% evidence 11.0/25 ROCE 1.2% · OPM 7.2% 76% evidence 10.4/20 P/E 32.7× · PEG — 15% evidence 12.2/20 RS sector 1.7% · RS bench 1% · 1Y -3.7%11 of 12 weeks ahead 70% evidence
Exact sum: 8.6 + 11 + 10.4 + 12.2 = 42.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Doximity, Inc.DOCS 40.7/100Mixed-negative evidence81% evidence ASLEEP 11.6/35 Revenue 13% · PAT -11.7% · OPM change -18.1 pp 83% evidence 15.9/25 ROCE 2.4% · OPM 17.1% 76% evidence 11.3/20 P/E 23.8× · PEG 1.84 65% evidence 1.9/20 RS sector -49.3% · RS bench -50.6% · 1Y -67.1%0 of 12 weeks ahead 100% evidence
Exact sum: 11.6 + 15.9 + 11.3 + 1.9 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20Talkspace, Inc.TALK 40.6/100Mixed-negative evidence64% evidence ASLEEP 12.9/35 Revenue 22.7% · PAT -66.7% · OPM change -9.5 pp 62% evidence 6.0/25 ROCE -6.2% · OPM -11.6% 76% evidence 8.5/20 P/E 517.5× · PEG — 15% evidence 13.2/20 RS sector 8.3% · RS bench 12% · 1Y 106%0 of 12 weeks ahead 100% evidence
Exact sum: 12.9 + 6 + 8.5 + 13.2 = 40.6 · Decision use: Price leads the evidence: RS versus the benchmark is 12%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
21HeartFlow, Inc.HTFL 39.7/100Thin evidence · provisional55% evidence ASLEEP 20.1/35 Revenue 40.4% · PAT — · OPM change -9.1 pp 62% evidence 4.0/25 ROCE -13.2% · OPM -56.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 5.6/20 RS sector -18% · RS bench -17.4% · 1Y -12.5%6 of 12 weeks ahead 70% evidence
Exact sum: 20.1 + 4 + 10 + 5.6 = 39.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
22Schrödinger, Inc.SDGR 37.5/100Thin evidence · provisional58% evidence BREAKING OUT 15.8/35 Revenue 10.9% · PAT — · OPM change 2.2 pp 62% evidence 4.9/25 ROCE -9.4% · OPM -83.3% 76% evidence 9.6/20 P/E 66.3× · PEG — 15% evidence 7.2/20 RS sector -11.9% · RS bench -12.2% · 1Y -18.5%10 of 12 weeks ahead 70% evidence
Exact sum: 15.8 + 4.9 + 9.6 + 7.2 = 37.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
23Tempus AI, Inc.TEM 37.1/100Thin evidence · provisional55% evidence ASLEEP 19.0/35 Revenue — · PAT — · OPM change 2.6 pp 45% evidence 5.4/25 ROCE -4.8% · OPM -24.3% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 2.7/20 RS sector -32.9% · RS bench -33.2% · 1Y -22.7%3 of 12 weeks ahead 100% evidence
Exact sum: 19 + 5.4 + 10 + 2.7 = 37.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
24Spok Holdings, Inc.SPOK 36.0/100Mixed-negative evidence75% evidence BASING 8.4/35 Revenue -1.4% · PAT -18.8% · OPM change -9.2 pp 83% evidence 13.0/25 ROCE 1.6% · OPM 7.4% 76% evidence 9.7/20 P/E 18.2× · PEG 2.25 65% evidence 4.9/20 RS sector -23.7% · RS bench -23.5% · 1Y -38.4%0 of 12 weeks ahead 70% evidence
Exact sum: 8.4 + 13 + 9.7 + 4.9 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25Claritev CorporationCTEV 36.0/100Thin evidence · provisional55% evidence ASLEEP 13.1/35 Revenue 5.8% · PAT — · OPM change -3.1 pp 62% evidence 8.9/25 ROCE 0.1% · OPM 2.7% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 4.0/20 RS sector -33.5% · RS bench -35.5% · 1Y -53.5%8 of 12 weeks ahead 70% evidence
Exact sum: 13.1 + 8.9 + 10 + 4 = 36 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
26Certara, Inc.CERT 35.6/100Thin evidence · provisional58% evidence BREAKING OUT 12.0/35 Revenue 6.8% · PAT — · OPM change -11.2 pp 62% evidence 8.8/25 ROCE -0.3% · OPM -4% 76% evidence 8.7/20 P/E 174.6× · PEG — 15% evidence 6.1/20 RS sector -14.8% · RS bench -15.5% · 1Y -28.7%6 of 12 weeks ahead 70% evidence
Exact sum: 12 + 8.8 + 8.7 + 6.1 = 35.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27Evolent Health, Inc.EVH 32.7/100Thin evidence · provisional55% evidence ASLEEP 11.3/35 Revenue -21.3% · PAT — · OPM change -1.8 pp 62% evidence 8.1/25 ROCE -0.6% · OPM -2.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 3.3/20 RS sector -42.2% · RS bench -43.6% · 1Y -65.4%10 of 12 weeks ahead 70% evidence
Exact sum: 11.3 + 8.1 + 10 + 3.3 = 32.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
28LifeMD, Inc.LFMD 31.0/100Thin evidence · provisional58% evidence ASLEEP 12.3/35 Revenue 36.9% · PAT — · OPM change -15.5 pp 62% evidence 4.0/25 ROCE -53.7% · OPM -17.8% 76% evidence 9.4/20 P/E 72.2× · PEG — 15% evidence 5.3/20 RS sector -21.5% · RS bench -21.8% · 1Y -42.8%7 of 12 weeks ahead 70% evidence
Exact sum: 12.3 + 4 + 9.4 + 5.3 = 31 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Teladoc Health, Inc.TDOC 41.9/100Thin evidence · provisional49% evidence ASLEEP 18.6/35 Revenue — · PAT — · OPM change 9.1 pp 45% evidence 6.8/25 ROCE -1.9% · OPM -10.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 6.5/20 RS sector -14.6% · RS bench -14.6% · 1Y -3.6%10 of 12 weeks ahead 70% evidence
Exact sum: 18.6 + 6.8 + 10 + 6.5 = 41.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
Showing 10 of 29 companies
04 · what price has already done

Market action

10x Genomics, Inc. has the strongest one-year price move in Health Information Services at +289.4%. It also leads on Mansfield relative strength against the S&P 500 at +96.6%. 12 of 29 covered companies are above zero on that measure. Every line covers 314 weekly closes through 2026-08-04.

Price and relative strength

Every company, the sector's own index and S&P 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

05 · compare level, then change

Revenue Scale & Growth Durability

Veeva Systems Inc. has the highest Revenue among the 29 Health Information Services companies compared here, at $3,319 million. Privia Health Group, Inc. is next at $2,246 million. Carlsmed, Inc. has the highest Revenue growth at 75%, so level and change sit with different companies. 22 of 29 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Veeva Systems Inc. is the scale leader at $3,319 million, 47.8% ahead of Privia Health Group, Inc.. Carlsmed, Inc.'s growth is 75% from a $56 million base, with 13 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

LeaderVeeva Systems Inc. · $3,319 million
Gap47.8% versus #2 · Privia Health Group, Inc.
Persistence8/8 recent comparable periods
Coverage22/29 companies · 522 observations

Investor read: Veeva Systems Inc. is the scale benchmark; Carlsmed, Inc. is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Veeva Systems Inc.'s growth falls below Carlsmed, Inc.'s for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1Veeva Systems Inc. VEEV$3.3B
2Privia Health Group, Inc. PRVA$2.2B
3Evolent Health, Inc. EVH$1.9B
4HealthEquity, Inc. HQY$1.3B
5Claritev Corporation CTEV$980M
Revenue growthfastest growers
1Carlsmed, Inc. CARL75%
2Hinge Health, Inc. HNGE50%
3Omada Health, Inc. OMDA49%
4HeartFlow, Inc. HTFL40%
5LifeMD, Inc. LFMD37%
Revenue · company comparison
22/29 level · 22/29 change

On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

CompanyRevenueRevenue growthReported
BrightSpring Health Services, Inc. BTSG$3.6B26%Jun 2026
Veeva Systems Inc. VEEV$883M16%Jun 2026
Teladoc Health, Inc. TDOC$614M-2.4%Jun 2026
Privia Health Group, Inc. PRVA$604M26%Mar 2026
Evolent Health, Inc. EVH$496M2.5%Mar 2026
HealthEquity, Inc. HQY$355M7.3%Jun 2026
Tempus AI, Inc. TEM$348M36%Jun 2026
Waystar Holding Corp. WAY$314M23%Jun 2026
Omnicell, Inc. OMCL$310M15%Jun 2026
Claritev Corporation CTEV$245M6.1%Mar 2026
GoodRx Holdings, Inc. GDRX$194M-4.4%Mar 2026
Hinge Health, Inc. HNGE$182M47%Mar 2026
10x Genomics, Inc. TXG$151M-2.6%Mar 2026
Doximity, Inc. DOCS$145M5.1%Mar 2026
Phreesia, Inc. PHR$131M13%Jun 2026
Certara, Inc. CERT$107M0.9%Mar 2026
TruBridge, Inc. TBRG$86M-1.2%Mar 2026
HealthStream, Inc. HSTM$81M11%Mar 2026
Omada Health, Inc. OMDA$78M42%Mar 2026
Weave Communications, Inc. WEAV$66M18%Mar 2026
Talkspace, Inc. TALK$62M19%Mar 2026
Schrödinger, Inc. SDGR$59M-1.7%Mar 2026
HeartFlow, Inc. HTFL$53M43%Mar 2026
LifeMD, Inc. LFMD$50M-2.0%Mar 2026
NRC Health NRC$35M2.9%Jun 2026
Spok Holdings, Inc. SPOK$33M-8.3%Mar 2026
Simulations Plus, Inc. SLP$24M9.1%Jun 2026
SOPHiA GENETICS SA SOPH$22M22%Mar 2026
Carlsmed, Inc. CARL$16M60%Mar 2026
Full 20-quarter history · every available company

Revenue · reported quarter history

Showing the 12 largest of 29 companies with a series here. The remaining 17 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

10x Genomics, Inc. · TXG

$125M
$144M
$114M
$115M
$131M
$156M
$134M
$147M
$154M
$184M
$141M
$153M
$152M
$165M
$155M
$173M
$149M
$166M
$151M
—

BrightSpring Health Services, Inc. · BTSG

$1.7B
$1.8B
$1.8B
$1.9B
$2.0B
$2.0B
$2.0B
$2.2B
$2.3B
$2.4B
$2.3B
$2.4B
$2.6B
$2.7B
$2.9B
$3.1B
$3.3B
$3.6B
$3.6B
—

Doximity, Inc. · DOCS

$79M
$98M
$94M
$91M
$102M
$115M
$111M
$108M
$114M
$135M
$118M
$127M
$137M
$169M
$138M
$146M
$169M
$185M
$145M
—

HealthEquity, Inc. · HQY

$189M
$180M
$203M
$206M
$206M
$216M
$234M
$244M
$244M
$249M
$262M
$288M
$300M
$300M
$312M
$331M
$326M
$322M
$335M
$355M

HeartFlow, Inc. · HTFL

—
—
—
—
—
—
—
—
—
—
$27M
$31M
$33M
$35M
$37M
$43M
$46M
$49M
$53M
—

Hinge Health, Inc. · HNGE

—
—
—
—
—
—
$124M
$70M
$81M
$82M
$83M
$90M
$101M
$117M
$124M
$139M
$154M
$171M
$182M
—

Omnicell, Inc. · OMCL

$296M
$311M
$319M
$331M
$348M
$298M
$291M
$299M
$299M
$259M
$246M
$277M
$282M
$307M
$270M
$291M
$311M
$314M
$310M
—

Privia Health Group, Inc. · PRVA

$252M
$275M
$314M
$336M
$343M
$364M
$386M
$413M
$417M
$441M
$415M
$422M
$438M
$461M
$480M
$521M
$580M
$541M
$604M
—

Teladoc Health, Inc. · TDOC

$522M
$554M
$565M
$592M
$611M
$638M
$629M
$652M
$660M
$661M
$646M
$642M
$641M
$640M
$629M
$632M
$626M
$642M
$614M
—

Tempus AI, Inc. · TEM

$52M
$63M
$64M
$78M
$88M
$101M
$116M
$132M
$136M
$148M
$146M
$166M
$181M
$201M
$256M
$315M
$334M
$367M
$348M
—

Veeva Systems Inc. · VEEV

$456M
$476M
$485M
$505M
$534M
$552M
$563M
$526M
$590M
$617M
$631M
$650M
$676M
$699M
$721M
$759M
$789M
$811M
$836M
$883M

Waystar Holding Corp. · WAY

$147M
$163M
$171M
$173M
$178M
$182M
$191M
$196M
$197M
$207M
$225M
$235M
$240M
$244M
$256M
$271M
$269M
$304M
$314M
—

Revenue growth · reported quarter history

Showing the 12 largest of 29 companies with a series here. The remaining 17 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

10x Genomics, Inc. · TXG

—
—
—
-0.9%
4.8%
8.3%
18%
28%
18%
18%
5.2%
4.1%
-1.3%
-10%
9.9%
13%
-2.0%
0.6%
-2.6%
—

BrightSpring Health Services, Inc. · BTSG

—
—
—
23%
14%
9.4%
11%
12%
14%
21%
13%
13%
15%
16%
26%
29%
28%
29%
26%
—

Doximity, Inc. · DOCS

—
—
—
25%
29%
17%
18%
19%
12%
17%
6.3%
18%
20%
25%
17%
15%
23%
9.5%
5.1%
—

HealthEquity, Inc. · HQY

—
—
—
—
9.0%
20%
15%
18%
18%
15%
12%
18%
23%
20%
19%
15%
8.7%
7.3%
7.4%
7.3%

HeartFlow, Inc. · HTFL

—
—
—
—
—
—
—
—
—
—
—
—
—
—
37%
39%
39%
40%
43%
—

Hinge Health, Inc. · HNGE

—
—
—
—
—
—
—
—
—
—
-33%
29%
25%
43%
49%
54%
52%
46%
47%
—

Omnicell, Inc. · OMCL

—
—
—
21%
18%
-4.2%
-8.8%
-9.7%
-14%
-13%
-15%
-7.4%
-5.7%
19%
9.8%
5.1%
10%
2.3%
15%
—

Privia Health Group, Inc. · PRVA

—
—
—
49%
36%
32%
23%
23%
22%
21%
7.5%
2.2%
5.0%
4.5%
16%
23%
32%
17%
26%
—

Teladoc Health, Inc. · TDOC

—
—
—
18%
17%
15%
11%
10%
8.0%
3.6%
2.7%
-1.5%
-2.9%
-3.2%
-2.6%
-1.6%
-2.3%
0.3%
-2.4%
—

Tempus AI, Inc. · TEM

—
—
—
26%
69%
60%
81%
69%
55%
47%
26%
26%
33%
36%
75%
90%
85%
83%
36%
—

Veeva Systems Inc. · VEEV

—
—
—
—
17%
16%
16%
4.2%
10%
12%
12%
24%
15%
13%
14%
17%
17%
16%
16%
16%

Waystar Holding Corp. · WAY

—
—
—
27%
21%
12%
12%
13%
11%
14%
18%
20%
22%
18%
14%
15%
12%
25%
23%
—
06 · compare level, then change

Operating Economics & Margin Trend

Veeva Systems Inc. has the highest OPM among the 29 Health Information Services companies compared here, at 30.9%. HealthEquity, Inc. is next at 29%. 10x Genomics, Inc. has the highest Margin change at +14.1 percentage points, so level and change sit with different companies. 29 of 29 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Veeva Systems Inc. leads opm at 30.9%; 10x Genomics, Inc. leads margin change at +14.1 percentage points.

LeaderVeeva Systems Inc. · 30.9%
Gap6.6% versus #2 · HealthEquity, Inc.
Persistence7/8 recent comparable periods
Coverage29/29 companies · 521 observations

Investor read: Veeva Systems Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1Veeva Systems Inc. VEEV31%
2HealthEquity, Inc. HQY29%
3Waystar Holding Corp. WAY26%
4Simulations Plus, Inc. SLP23%
5Hinge Health, Inc. HNGE18%
Margin changefastest expanders
110x Genomics, Inc. TXG+14.1 pp
2Simulations Plus, Inc. SLP+11.1 pp
3SOPHiA GENETICS SA SOPH+10.5 pp
4Omnicell, Inc. OMCL+9.7 pp
5Omada Health, Inc. OMDA+9.2 pp
Operating margin · company comparison
29/29 level · 29/29 change
All-company data · latest reported quarter
CompanyOPMMargin changeReported
Veeva Systems Inc. VEEV31%+0.1 ppJun 2026
HealthEquity, Inc. HQY29%+3.9 ppJun 2026
Waystar Holding Corp. WAY26%+0.2 ppJun 2026
Simulations Plus, Inc. SLP23%+11.1 ppJun 2026
Hinge Health, Inc. HNGE18%+7.0 ppMar 2026
Doximity, Inc. DOCS17%−18.1 ppMar 2026
NRC Health NRC16%−9.6 ppJun 2026
HealthStream, Inc. HSTM9.3%+3.3 ppMar 2026
Spok Holdings, Inc. SPOK7.4%−9.2 ppMar 2026
GoodRx Holdings, Inc. GDRX7.2%−4.3 ppMar 2026
Omnicell, Inc. OMCL5.4%+9.7 ppJun 2026
Phreesia, Inc. PHR5.2%+8.0 ppJun 2026
TruBridge, Inc. TBRG3.5%−5.9 ppMar 2026
BrightSpring Health Services, Inc. BTSG3.4%+1.6 ppJun 2026
Claritev Corporation CTEV2.7%−3.1 ppMar 2026
Privia Health Group, Inc. PRVA1.2%+0.1 ppMar 2026
Evolent Health, Inc. EVH-2.1%−1.8 ppMar 2026
Certara, Inc. CERT-4.0%−11.2 ppMar 2026
Omada Health, Inc. OMDA-6.1%+9.2 ppMar 2026
Weave Communications, Inc. WEAV-9.2%+7.5 ppMar 2026
Teladoc Health, Inc. TDOC-10%+9.1 ppJun 2026
10x Genomics, Inc. TXG-11%+14.1 ppMar 2026
Talkspace, Inc. TALK-12%−9.5 ppMar 2026
LifeMD, Inc. LFMD-18%−15.5 ppMar 2026
Tempus AI, Inc. TEM-24%+2.6 ppJun 2026
HeartFlow, Inc. HTFL-56%−9.1 ppMar 2026
Carlsmed, Inc. CARL-58%−1.5 ppMar 2026
SOPHiA GENETICS SA SOPH-80%+10.5 ppMar 2026
Schrödinger, Inc. SDGR-83%+2.2 ppMar 2026
Full 20-quarter history · every available company

OPM · reported quarter history

Showing the 12 largest of 29 companies with a series here. The remaining 17 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

10x Genomics, Inc. · TXG

-13%
-11%
-37%
-55%
-31%
-15%
-39%
-43%
-62%
-30%
-44%
-27%
-27%
-30%
-25%
17%
-22%
-12%
-11%
—

BrightSpring Health Services, Inc. · BTSG

3.9%
3.5%
3.3%
3.5%
1.8%
1.2%
2.5%
3.7%
-2.3%
2.9%
-0.7%
1.6%
1.1%
2.0%
1.8%
1.5%
2.6%
3.0%
3.4%
—

Doximity, Inc. · DOCS

31%
37%
30%
24%
31%
33%
30%
27%
30%
43%
36%
36%
39%
47%
35%
37%
38%
39%
17%
—

HealthEquity, Inc. · HQY

-0.5%
-0.2%
-13%
-3.5%
-1.2%
2.6%
5.7%
9.5%
10%
12%
15%
15%
20%
6.5%
14%
25%
28%
24%
21%
29%

HeartFlow, Inc. · HTFL

—
—
—
—
—
—
—
—
—
—
-60%
-46%
-45%
-46%
-47%
-32%
-33%
-36%
-56%
—

Hinge Health, Inc. · HNGE

—
—
—
—
—
—
11%
-53%
-27%
-37%
-38%
-20%
-3.8%
36%
11%
-418%
-4.0%
16%
18%
—

Omnicell, Inc. · OMCL

9.9%
3.7%
1.6%
3.8%
5.3%
-13%
-7.9%
2.6%
1.2%
-9.0%
-8.9%
1.2%
2.3%
4.0%
-4.3%
2.8%
2.7%
0.1%
5.4%
—

Privia Health Group, Inc. · PRVA

-5.1%
-7.0%
-3.7%
-1.6%
-1.3%
0.6%
1.7%
1.7%
1.3%
0.3%
0.2%
1.2%
1.3%
1.1%
1.1%
0.6%
2.5%
2.1%
1.2%
—

Teladoc Health, Inc. · TDOC

-12%
2.0%
—
-523%
-12%
-586%
-12%
-11%
-9.8%
-5.3%
-14%
-131%
-6.9%
-7.5%
-19%
-8.6%
-8.3%
-5.6%
-10%
—

Tempus AI, Inc. · TEM

-123%
-87%
-120%
-85%
-72%
-58%
-47%
-34%
-33%
-35%
-37%
-321%
-30%
-25%
-27%
-20%
-18%
-17%
-24%
—

Veeva Systems Inc. · VEEV

27%
28%
25%
25%
19%
22%
19%
12%
18%
21%
21%
24%
25%
44%
-21%
31%
25%
45%
-18%
31%

Waystar Holding Corp. · WAY

11%
7.2%
9.0%
12%
14%
16%
18%
19%
16%
18%
16%
3.5%
11%
22%
25%
24%
22%
19%
26%
—

Margin change · reported quarter history

Showing the 12 largest of 29 companies with a series here. The remaining 17 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

10x Genomics, Inc. · TXG

—
—
—
−46.2 pp
−17.8 pp
−3.8 pp
−2.2 pp
+11.9 pp
−31.2 pp
−15.2 pp
−4.9 pp
+15.9 pp
+34.3 pp
−0.2 pp
+18.2 pp
+44.7 pp
+5.8 pp
+18.4 pp
+14.1 pp
—

BrightSpring Health Services, Inc. · BTSG

—
—
—
+0.2 pp
−2.1 pp
−2.3 pp
−0.8 pp
+0.2 pp
−4.1 pp
+1.7 pp
−3.2 pp
−2.1 pp
+3.4 pp
−0.9 pp
+2.5 pp
−0.1 pp
+1.5 pp
+1.0 pp
+1.6 pp
—

Doximity, Inc. · DOCS

—
—
—
−10.3 pp
0.0 pp
−3.2 pp
−0.2 pp
+3.5 pp
−1.7 pp
+9.9 pp
+5.9 pp
+9.0 pp
+9.1 pp
+4.1 pp
−0.3 pp
+1.0 pp
−1.0 pp
−8.5 pp
−18.1 pp
—

HealthEquity, Inc. · HQY

—
—
—
—
−0.7 pp
+2.8 pp
+19.1 pp
+13.0 pp
+11.4 pp
+9.8 pp
+9.1 pp
+5.0 pp
+9.4 pp
−5.9 pp
−1.3 pp
+10.6 pp
+7.9 pp
+17.9 pp
+7.7 pp
+3.9 pp

HeartFlow, Inc. · HTFL

—
—
—
—
—
—
—
—
—
—
—
—
—
—
+12.8 pp
+14.1 pp
+12.7 pp
+9.8 pp
−9.1 pp
—

Hinge Health, Inc. · HNGE

—
—
—
—
—
—
—
—
—
—
−48.6 pp
+33.7 pp
+23.6 pp
+73.1 pp
+48.6 pp
−398.0 pp
−0.2 pp
−19.7 pp
+7.0 pp
—

Omnicell, Inc. · OMCL

—
—
—
−6.8 pp
−4.6 pp
−16.6 pp
−9.5 pp
−1.2 pp
−4.1 pp
+3.9 pp
−1.0 pp
−1.4 pp
+1.1 pp
+13.0 pp
+4.6 pp
+1.6 pp
+0.4 pp
−3.9 pp
+9.7 pp
—

Privia Health Group, Inc. · PRVA

—
—
—
+84.0 pp
+3.8 pp
+7.6 pp
+5.4 pp
+3.3 pp
+2.6 pp
−0.3 pp
−1.5 pp
−0.5 pp
0.0 pp
+0.8 pp
+0.9 pp
−0.6 pp
+1.2 pp
+1.0 pp
+0.1 pp
—

Teladoc Health, Inc. · TDOC

—
—
—
−507.0 pp
−0.1 pp
−588.4 pp
+1,167.4 pp
+511.7 pp
+1.9 pp
+581.1 pp
−1.2 pp
−119.9 pp
+2.9 pp
−2.2 pp
−5.7 pp
+122.3 pp
−1.4 pp
+1.9 pp
+9.1 pp
—

Tempus AI, Inc. · TEM

—
—
—
+16.4 pp
+51.0 pp
+28.2 pp
+73.5 pp
+50.9 pp
+39.3 pp
+22.9 pp
+10.1 pp
−287.3 pp
+3.3 pp
+10.1 pp
+9.6 pp
+301.8 pp
+11.3 pp
+8.6 pp
+2.6 pp
—

Veeva Systems Inc. · VEEV

—
—
—
—
−8.5 pp
−5.9 pp
−5.4 pp
−13.6 pp
−1.3 pp
−1.2 pp
+2.1 pp
+12.2 pp
+7.0 pp
+22.7 pp
−42.7 pp
+6.9 pp
+0.2 pp
+1.5 pp
+3.2 pp
+0.1 pp

Waystar Holding Corp. · WAY

—
—
—
−0.5 pp
+3.2 pp
+8.5 pp
+9.3 pp
+6.8 pp
+2.6 pp
+2.5 pp
−2.6 pp
−15.5 pp
−5.0 pp
+3.6 pp
+9.7 pp
+20.5 pp
+11.1 pp
−2.4 pp
+0.2 pp
—
07 · compare level, then change

Profit Scale & Acceleration

Veeva Systems Inc. has the highest Net profit among the 29 Health Information Services companies compared here, at $941 million. HealthEquity, Inc. is next at $231 million. HealthEquity, Inc. has the highest Profit growth at 89.3%, so level and change sit with different companies. 22 of 29 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Veeva Systems Inc. leads with $941 million of TTM profit, 307.4% above HealthEquity, Inc.. HealthEquity, Inc. shows 89.3% growth from a $231 million profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

LeaderVeeva Systems Inc. · $941 million
Gap307.4% versus #2 · HealthEquity, Inc.
Persistence8/8 recent comparable periods
Coverage22/29 companies · 522 observations

Investor read: Veeva Systems Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1Veeva Systems Inc. VEEV$941M
2HealthEquity, Inc. HQY$231M
3Doximity, Inc. DOCS$196M
4Phreesia, Inc. PHR$111M
5Privia Health Group, Inc. PRVA$28M
Profit growthfastest growers
1HealthEquity, Inc. HQY89%
2Privia Health Group, Inc. PRVA40%
3Veeva Systems Inc. VEEV21%
4HealthStream, Inc. HSTM5.3%
5Doximity, Inc. DOCS-12%
Net profit · company comparison
22/29 level · 8/29 change
All-company data · latest reported quarter
CompanyNet profitProfit growthReported
Veeva Systems Inc. VEEV$261M14%Jun 2026
BrightSpring Health Services, Inc. BTSG$74M722%Jun 2026
HealthEquity, Inc. HQY$69M28%Jun 2026
Waystar Holding Corp. WAY$43M48%Jun 2026
Hinge Health, Inc. HNGE$35M106%Mar 2026
Doximity, Inc. DOCS$19M-69%Mar 2026
Omnicell, Inc. OMCL$11M-113%Jun 2026
HealthStream, Inc. HSTM$6M50%Mar 2026
Simulations Plus, Inc. SLP$5M67%Jun 2026
Privia Health Group, Inc. PRVA$4M-33%Mar 2026
Phreesia, Inc. PHR$3M18%Jun 2026
NRC Health NRC$3M-50%Jun 2026
Spok Holdings, Inc. SPOK$2M-60%Mar 2026
GoodRx Holdings, Inc. GDRX$1M-91%Mar 2026
TruBridge, Inc. TBRG$1M-167%Mar 2026
Omada Health, Inc. OMDA$-3M—Mar 2026
Talkspace, Inc. TALK$-6M400%Mar 2026
Weave Communications, Inc. WEAV$-6M—Mar 2026
Certara, Inc. CERT$-9M-280%Mar 2026
Carlsmed, Inc. CARL$-9M—Mar 2026
LifeMD, Inc. LFMD$-9M-107%Mar 2026
10x Genomics, Inc. TXG$-13M—Mar 2026
SOPHiA GENETICS SA SOPH$-19M—Mar 2026
HeartFlow, Inc. HTFL$-27M—Mar 2026
Evolent Health, Inc. EVH$-27M-1,100%Mar 2026
Schrödinger, Inc. SDGR$-60M-1,450%Mar 2026
Teladoc Health, Inc. TDOC$-64M—Jun 2026
Tempus AI, Inc. TEM$-123M—Jun 2026
Claritev Corporation CTEV$-147M-220%Mar 2026
Full 20-quarter history · every available company

Net profit · reported quarter history

Showing the 12 largest of 29 companies with a series here. The remaining 17 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

10x Genomics, Inc. · TXG

$-17M
$-18M
$-42M
$-64M
$-42M
$-17M
$-51M
$-62M
$-93M
$-49M
$-60M
$-38M
$-36M
$-49M
$-34M
$35M
$-27M
$-16M
$-13M
—

BrightSpring Health Services, Inc. · BTSG

$17M
$15M
$11M
$14M
$-23M
$-57M
$-22M
$3M
$-130M
$-7M
$-56M
$8M
$-26M
$4M
$9M
$9M
$37M
$50M
$74M
—

Doximity, Inc. · DOCS

$36M
$56M
$37M
$22M
$26M
$33M
$31M
$28M
$31M
$48M
$41M
$41M
$44M
$75M
$62M
$53M
$62M
$62M
$19M
—

HealthEquity, Inc. · HQY

$-4M
$-5M
$-33M
$-14M
$-11M
$-2M
$0M
$4M
$11M
$15M
$26M
$29M
$36M
$6M
$26M
$54M
$60M
$52M
$50M
$69M

HeartFlow, Inc. · HTFL

—
—
—
—
—
—
—
—
—
—
$-21M
$-23M
$-19M
$-33M
$-32M
$-9M
$-51M
$-24M
$-27M
—

Hinge Health, Inc. · HNGE

—
—
—
—
—
—
$17M
$-32M
$-17M
$-24M
$-26M
$-13M
$0M
$27M
$17M
$-576M
$-2M
$32M
$35M
—

Omnicell, Inc. · OMCL

$29M
$14M
$8M
$9M
$17M
$-28M
$-15M
$3M
$6M
$-14M
$-16M
$4M
$9M
$16M
$-7M
$6M
$5M
$-2M
$11M
—

Privia Health Group, Inc. · PRVA

$-11M
$-12M
$-18M
$-11M
$1M
$17M
$6M
$6M
$6M
$2M
$3M
$5M
$4M
$5M
$6M
$3M
$10M
$11M
$4M
—

Teladoc Health, Inc. · TDOC

$-84M
$-11M
$-6.7B
$-3.1B
$-73M
$-3.8B
$-69M
$-65M
$-57M
$-29M
$-82M
$-838M
$-33M
$-48M
$-93M
$-33M
$-50M
$-25M
$-64M
—

Tempus AI, Inc. · TEM

$-65M
$-55M
$-77M
$-67M
$-63M
$-59M
$-54M
$-56M
$-53M
$-50M
$-65M
$-552M
$-74M
$-10M
$-66M
$-41M
$-82M
$-51M
$-123M
—

Veeva Systems Inc. · VEEV

$109M
$106M
$97M
$100M
$91M
$108M
$189M
$132M
$112M
$135M
$147M
$162M
$171M
$186M
$196M
$228M
$200M
$236M
$244M
$261M

Waystar Holding Corp. · WAY

$-12M
$-15M
$-15M
$-11M
$-10M
$-16M
$-11M
$-11M
$-15M
$-14M
$-16M
$-28M
$5M
$19M
$29M
$32M
$31M
$20M
$43M
—

Profit growth · reported quarter history

Showing the 12 largest of 21 companies with a series here. The remaining 9 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

BrightSpring Health Services, Inc. · BTSG

—
—
—
56%
-235%
-480%
-300%
-79%
—
—
—
167%
—
—
—
13%
—
1,150%
722%
—

Certara, Inc. · CERT

—
—
—
—
—
—
-50%
—
-1,325%
-233%
-600%
-360%
—
—
—
—
—
-186%
-280%
—

Doximity, Inc. · DOCS

—
—
—
-15%
-28%
-41%
-16%
27%
19%
45%
32%
46%
42%
56%
51%
29%
41%
-17%
-69%
—

GoodRx Holdings, Inc. · GDRX

—
—
—
-103%
—
—
-125%
—
—
—
—
-88%
—
—
—
86%
-75%
-29%
-91%
—

HealthEquity, Inc. · HQY

—
—
—
—
—
—
—
—
—
—
—
625%
227%
-60%
0.0%
86%
67%
767%
92%
28%

HealthStream, Inc. · HSTM

—
—
—
50%
100%
—
0.0%
33%
0.0%
150%
67%
0.0%
50%
0.0%
-20%
25%
0.0%
-40%
50%
—

Hinge Health, Inc. · HNGE

—
—
—
—
—
—
—
—
—
—
-253%
—
—
—
—
—
—
19%
106%
—

Omnicell, Inc. · OMCL

—
—
—
-55%
-41%
-300%
-288%
-67%
-65%
—
—
33%
50%
—
—
50%
-44%
-113%
—
—

Privia Health Group, Inc. · PRVA

—
—
—
—
—
—
—
—
500%
-88%
-50%
-17%
-33%
150%
100%
-40%
150%
120%
-33%
—

Schrödinger, Inc. · SDGR

—
—
—
—
—
—
—
—
—
—
-143%
-1,450%
—
—
—
—
—
—
—
—

Veeva Systems Inc. · VEEV

—
—
—
—
-17%
1.9%
95%
32%
23%
25%
-22%
23%
53%
38%
33%
41%
17%
27%
24%
14%

Waystar Holding Corp. · WAY

—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
520%
5.3%
48%
—
08 · compare level, then change

Return On Capital Employed

Hinge Health, Inc. has the highest ROCE among the 29 Health Information Services companies compared here, at 8.4%. Veeva Systems Inc. is next at 4%. Simulations Plus, Inc. has the highest ROCE change at +52 percentage points, so level and change sit with different companies. 29 of 29 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Hinge Health, Inc. leads ROCE at 8.4%, 4.4 percentage points above Veeva Systems Inc.. Simulations Plus, Inc. has the strongest latest improvement at +52 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

LeaderHinge Health, Inc. · 8.4%
Gap110% versus #2 · Veeva Systems Inc.
Persistence3/5 recent comparable periods
Coverage29/29 companies · 516 observations

Investor read: Hinge Health, Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1Hinge Health, Inc. HNGE8.4%
2Veeva Systems Inc. VEEV4.0%
3Simulations Plus, Inc. SLP3.4%
4HealthEquity, Inc. HQY3.2%
5BrightSpring Health Services, Inc. BTSG2.9%
ROCE changefastest improvers
1Simulations Plus, Inc. SLP+52.0 pp
2Omada Health, Inc. OMDA+15.4 pp
3HeartFlow, Inc. HTFL+11.6 pp
4Carlsmed, Inc. CARL+11.4 pp
5Phreesia, Inc. PHR+2.9 pp
Return on capital · company comparison
29/29 level · 29/29 change
All-company data · latest reported quarter
CompanyROCEROCE changeReported
Hinge Health, Inc. HNGE8.4%+2.5 ppMar 2026
Veeva Systems Inc. VEEV4.0%−0.1 ppJun 2026
Simulations Plus, Inc. SLP3.4%+52.0 ppJun 2026
HealthEquity, Inc. HQY3.2%+0.6 ppJun 2026
BrightSpring Health Services, Inc. BTSG2.9%+1.8 ppJun 2026
Doximity, Inc. DOCS2.4%−2.4 ppMar 2026
Omnicell, Inc. OMCL2.1%+1.6 ppJun 2026
HealthStream, Inc. HSTM1.9%+0.8 ppMar 2026
Phreesia, Inc. PHR1.7%+2.9 ppJun 2026
Spok Holdings, Inc. SPOK1.6%−2.0 ppMar 2026
Waystar Holding Corp. WAY1.5%+0.1 ppJun 2026
GoodRx Holdings, Inc. GDRX1.2%−0.6 ppMar 2026
Privia Health Group, Inc. PRVA1.0%+0.2 ppMar 2026
TruBridge, Inc. TBRG0.9%−1.4 ppMar 2026
Claritev Corporation CTEV0.1%−0.1 ppMar 2026
Certara, Inc. CERT-0.3%−0.8 ppMar 2026
Evolent Health, Inc. EVH-0.6%−0.5 ppMar 2026
Teladoc Health, Inc. TDOC-1.9%+0.2 ppJun 2026
10x Genomics, Inc. TXG-2.0%+2.9 ppMar 2026
Omada Health, Inc. OMDA-2.9%+15.4 ppMar 2026
NRC Health NRC-3.1%−4.9 ppJun 2026
Tempus AI, Inc. TEM-4.8%+1.7 ppJun 2026
Weave Communications, Inc. WEAV-5.1%+2.8 ppMar 2026
Talkspace, Inc. TALK-6.2%−5.3 ppMar 2026
Schrödinger, Inc. SDGR-9.4%−1.0 ppMar 2026
Carlsmed, Inc. CARL-12%+11.4 ppMar 2026
HeartFlow, Inc. HTFL-13%+11.6 ppMar 2026
SOPHiA GENETICS SA SOPH-15%−3.1 ppMar 2026
LifeMD, Inc. LFMD-54%−45.7 ppMar 2026
Full 20-quarter history · every available company

ROCE · reported quarter history

Showing the 12 largest of 29 companies with a series here. The remaining 17 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

10x Genomics, Inc. · TXG

-1.8%
-1.8%
-4.8%
-7.2%
-4.5%
-2.6%
-5.7%
-7.1%
-11%
-6.4%
-7.2%
-4.9%
-5.0%
-6.1%
-4.9%
3.6%
-3.8%
-2.3%
-2.0%
—

BrightSpring Health Services, Inc. · BTSG

1.6%
1.5%
2.6%
3.0%
0.8%
0.5%
2.3%
3.5%
-1.2%
1.6%
-0.3%
0.9%
0.6%
1.3%
1.2%
1.1%
1.9%
2.4%
2.7%
2.9%

Doximity, Inc. · DOCS

6.5%
7.4%
5.4%
2.6%
3.8%
4.3%
3.5%
3.0%
3.7%
6.3%
4.3%
4.7%
5.6%
8.2%
4.8%
5.5%
6.1%
7.0%
2.4%
—

HealthEquity, Inc. · HQY

—
0.0%
-1.0%
-0.2%
-0.1%
0.2%
0.4%
0.8%
0.8%
1.0%
1.3%
1.4%
1.9%
0.6%
1.3%
2.6%
2.7%
2.4%
2.2%
3.2%

HeartFlow, Inc. · HTFL

—
—
—
—
—
—
—
—
0.0%
0.0%
—
—
-13%
-14%
-25%
-22%
-7.3%
-8.8%
-13%
—

Hinge Health, Inc. · HNGE

—
—
—
—
—
—
—
—
-5.1%
-7.0%
—
—
-0.9%
9.7%
5.9%
-306%
-1.5%
6.8%
8.4%
—

Omnicell, Inc. · OMCL

1.8%
0.9%
0.4%
0.7%
1.1%
-2.5%
-1.5%
0.4%
0.2%
-1.3%
-1.2%
0.2%
0.4%
0.7%
-0.7%
0.5%
0.6%
0.0%
1.1%
2.1%

Privia Health Group, Inc. · PRVA

-4.1%
-5.7%
-3.3%
-1.2%
-1.0%
0.4%
1.3%
1.3%
1.0%
0.2%
0.1%
0.8%
0.9%
0.8%
0.8%
0.5%
2.0%
1.5%
1.0%
—

Teladoc Health, Inc. · TDOC

-0.6%
0.1%
-48%
-25%
-0.6%
-35%
-1.0%
-1.2%
-1.1%
-0.9%
-2.2%
-26%
-1.4%
-1.5%
-3.8%
-2.1%
-2.0%
-1.4%
-2.5%
-1.9%

Tempus AI, Inc. · TEM

-12%
-10%
-30%
-26%
-13%
-13%
—
—
-11%
-13%
-41%
-156%
-11%
-11%
-9.4%
-6.5%
-4.6%
-4.8%
-5.6%
-4.8%

Veeva Systems Inc. · VEEV

—
5.3%
4.5%
4.5%
3.4%
3.8%
3.2%
1.7%
2.8%
3.2%
3.2%
3.5%
3.5%
6.0%
-2.9%
4.1%
3.3%
5.7%
-2.3%
4.0%

Waystar Holding Corp. · WAY

0.3%
0.3%
—
—
0.5%
0.6%
1.5%
1.6%
0.7%
0.8%
0.8%
0.2%
0.6%
1.2%
1.5%
1.4%
1.3%
1.2%
1.6%
1.5%

ROCE change · reported quarter history

Showing the 12 largest of 29 companies with a series here. The remaining 17 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

10x Genomics, Inc. · TXG

—
—
—
—
−2.7 pp
−0.8 pp
−0.9 pp
+0.1 pp
−6.6 pp
−3.8 pp
−1.5 pp
+2.2 pp
+6.1 pp
+0.3 pp
+2.3 pp
+8.5 pp
+1.2 pp
+3.8 pp
+2.9 pp
—

BrightSpring Health Services, Inc. · BTSG

—
—
—
—
−0.8 pp
−1.0 pp
−0.3 pp
+0.5 pp
−2.0 pp
+1.1 pp
−2.6 pp
−2.6 pp
+1.8 pp
−0.3 pp
+1.5 pp
+0.2 pp
+1.3 pp
+1.1 pp
+1.5 pp
+1.8 pp

Doximity, Inc. · DOCS

—
—
—
—
−2.7 pp
−3.1 pp
−1.9 pp
+0.4 pp
−0.1 pp
+2.0 pp
+0.8 pp
+1.7 pp
+1.9 pp
+1.9 pp
+0.5 pp
+0.8 pp
+0.5 pp
−1.2 pp
−2.4 pp
—

HealthEquity, Inc. · HQY

—
—
—
—
—
+0.2 pp
+1.4 pp
+1.0 pp
+0.9 pp
+0.8 pp
+0.9 pp
+0.6 pp
+1.1 pp
−0.4 pp
0.0 pp
+1.2 pp
+0.8 pp
+1.8 pp
+0.9 pp
+0.6 pp

HeartFlow, Inc. · HTFL

—
—
—
—
—
—
—
—
—
—
—
—
−12.6 pp
−13.5 pp
—
—
+5.3 pp
+4.7 pp
+11.6 pp
—

Hinge Health, Inc. · HNGE

—
—
—
—
—
—
—
—
—
—
—
—
+4.2 pp
+16.7 pp
—
—
−0.6 pp
−2.9 pp
+2.5 pp
—

Omnicell, Inc. · OMCL

—
—
—
—
−0.7 pp
−3.4 pp
−1.9 pp
−0.3 pp
−0.9 pp
+1.2 pp
+0.3 pp
−0.2 pp
+0.2 pp
+2.0 pp
+0.5 pp
+0.3 pp
+0.2 pp
−0.7 pp
+1.8 pp
+1.6 pp

Privia Health Group, Inc. · PRVA

—
—
—
—
+3.1 pp
+6.1 pp
+4.6 pp
+2.5 pp
+2.0 pp
−0.2 pp
−1.2 pp
−0.5 pp
−0.1 pp
+0.6 pp
+0.7 pp
−0.3 pp
+1.1 pp
+0.7 pp
+0.2 pp
—

Teladoc Health, Inc. · TDOC

—
—
—
—
0.0 pp
−35.1 pp
+46.5 pp
+23.5 pp
−0.5 pp
+34.1 pp
−1.2 pp
−24.6 pp
−0.3 pp
−0.6 pp
−1.6 pp
+23.7 pp
−0.6 pp
+0.1 pp
+1.3 pp
+0.2 pp

Tempus AI, Inc. · TEM

—
—
—
—
−1.5 pp
−3.1 pp
—
—
+2.1 pp
+0.1 pp
—
—
+0.7 pp
+2.8 pp
+31.6 pp
+149.7 pp
+5.9 pp
+5.7 pp
+3.8 pp
+1.7 pp

Veeva Systems Inc. · VEEV

—
—
—
—
—
−1.5 pp
−1.3 pp
−2.8 pp
−0.6 pp
−0.6 pp
0.0 pp
+1.8 pp
+0.7 pp
+2.8 pp
−6.1 pp
+0.6 pp
−0.2 pp
−0.3 pp
+0.6 pp
−0.1 pp

Waystar Holding Corp. · WAY

—
—
—
—
+0.2 pp
+0.3 pp
—
—
+0.2 pp
+0.2 pp
−0.7 pp
−1.4 pp
−0.1 pp
+0.4 pp
+0.7 pp
+1.2 pp
+0.7 pp
0.0 pp
+0.1 pp
+0.1 pp
09 · compare level, then change

Valuation Against Growth & Quality

Veeva Systems Inc. has the lowest PEG among the 29 Health Information Services companies compared here, at 1.47×. HealthEquity, Inc. is next at 1.57×. Spok Holdings, Inc. has the lowest P/E at 18.2×, so level and change sit with different companies. 6 of 29 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Veeva Systems Inc. has the lowest comparable PEG at 1.47×, 6.4% below HealthEquity, Inc.. Only 6 of 29 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

LeaderVeeva Systems Inc. · 1.47×
Gap6.4% versus #2 · HealthEquity, Inc.
Persistence0/8 recent comparable periods
Coverage6/29 companies · 39 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
1Veeva Systems Inc. VEEV1.5
2HealthEquity, Inc. HQY1.6
3Doximity, Inc. DOCS1.8
4Spok Holdings, Inc. SPOK2.3
5Privia Health Group, Inc. PRVA3.9
P/Elowest P/E
1Spok Holdings, Inc. SPOK18.2
2Doximity, Inc. DOCS23.8
3Veeva Systems Inc. VEEV27.8
4Waystar Holding Corp. WAY29.3
5HealthEquity, Inc. HQY30.7
Valuation · company comparison
6/29 level · 18/29 change
All-company data · latest reported quarter
CompanyPEGP/EReported
HealthStream, Inc. HSTM4.930.9Mar 2026
Privia Health Group, Inc. PRVA3.9128.6Mar 2026
Spok Holdings, Inc. SPOK2.318.2Mar 2026
Doximity, Inc. DOCS1.823.8Mar 2026
HealthEquity, Inc. HQY1.630.7Jun 2026
Veeva Systems Inc. VEEV1.527.8Jun 2026
BrightSpring Health Services, Inc. BTSG—44.4Jun 2026
Waystar Holding Corp. WAY—29.3Jun 2026
Omnicell, Inc. OMCL—49.4Jun 2026
Certara, Inc. CERT—174.6Mar 2026
Schrödinger, Inc. SDGR—66.3Mar 2026
GoodRx Holdings, Inc. GDRX—32.7Mar 2026
Talkspace, Inc. TALK—517.5Mar 2026
Phreesia, Inc. PHR—61.4Jun 2026
NRC Health NRC—86.3Jun 2026
TruBridge, Inc. TBRG—73.2Mar 2026
Simulations Plus, Inc. SLP—42.8Jun 2026
LifeMD, Inc. LFMD—72.2Mar 2026
Full 20-quarter history · every available company

PEG · reported quarter history

Doximity, Inc. · DOCS

—
—
—
—
—
—
—
—
—
2.1
1.0
0.8
1.0
1.0
1.0
1.1
1.3
1.8
—
—

HealthEquity, Inc. · HQY

—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
1.3
1.6
—
—
—

HealthStream, Inc. · HSTM

—
—
—
—
—
—
—
—
1.2
1.9
0.9
1.2
0.9
1.5
5.9
3.1
—
—
4.9
—

Privia Health Group, Inc. · PRVA

—
—
—
—
—
—
—
—
—
—
3.6
—
—
—
—
—
6.4
2.4
3.9
—

Spok Holdings, Inc. · SPOK

—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
2.7
2.3
—
—
—

Veeva Systems Inc. · VEEV

—
—
—
—
—
—
—
2.2
1.7
1.3
9.2
9.9
4.0
3.2
1.6
1.3
2.0
2.1
1.5
1.5

P/E · reported quarter history

Showing the 12 largest of 18 companies with a series here. The remaining 6 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.

BrightSpring Health Services, Inc. · BTSG

—
—
—
—
—
—
—
—
—
—
—
—
—
—
139.2
107.2
56.9
43.1
32.3
44.4

Certara, Inc. · CERT

—
—
—
—
—
178.6
267.9
151.8
—
—
—
—
—
—
—
234.0
174.6
—
—
—

Doximity, Inc. · DOCS

172.1
85.0
74.4
49.7
46.5
61.0
61.1
61.9
36.6
42.5
37.4
35.0
50.1
53.4
52.3
52.4
58.1
36.9
23.8
—

GoodRx Holdings, Inc. · GDRX

—
—
—
—
—
—
—
184.0
140.8
—
—
—
—
116.3
55.1
49.8
47.0
30.1
32.7
—

HealthEquity, Inc. · HQY

—
—
—
—
—
—
—
—
452.9
210.8
118.1
85.8
65.4
78.2
101.3
62.6
58.8
43.4
34.8
30.7

HealthStream, Inc. · HSTM

124.3
146.4
94.9
94.4
70.9
63.7
69.5
58.5
50.2
54.1
46.0
47.3
44.4
48.2
51.1
41.3
41.5
37.8
30.9
—

Omnicell, Inc. · OMCL

86.8
111.4
86.9
90.3
85.3
420.2
—
—
—
—
—
—
—
164.9
76.0
58.8
70.8
1,132.5
75.9
49.4

Privia Health Group, Inc. · PRVA

—
—
—
—
—
—
251.0
96.7
74.2
121.2
130.6
144.8
182.1
177.7
187.1
209.1
191.5
131.7
128.6
—

Schrödinger, Inc. · SDGR

—
—
—
—
—
—
202.5
58.1
50.5
66.3
—
—
—
—
—
—
—
—
—
—

Talkspace, Inc. · TALK

—
—
—
—
—
—
—
—
—
—
—
—
—
309.0
128.0
139.0
92.0
90.8
517.5
—

Veeva Systems Inc. · VEEV

—
118.7
89.9
71.6
92.0
68.6
56.9
56.0
61.5
55.4
64.4
58.6
51.2
51.6
54.0
49.5
58.4
56.7
37.5
27.8

Waystar Holding Corp. · WAY

—
—
—
—
—
—
—
—
—
—
—
—
—
—
415.1
85.2
61.2
53.7
36.0
29.3
10 · before the conclusion, check the blind spots

What can make this comparison misleading?

This Health Information Services comparison names 4 specific ways its own evidence can mislead, all listed below. All 29 companies here report on comparable dates, so no rank carries a stale marker. A high growth rate can still be a low-base artefact.

Keep these limits visible

  • A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
  • A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
  • The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
  • An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
11 · evidence and freshness

How was this comparison built?

This comparison is built from the reported filings of 29 Health Information Services companies, normalized to a common $ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-04. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.

FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-08-04 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
12 · questions investors ask, short speakable answers

Health Information Services company comparison FAQs

These 22 answers restate the Health Information Services comparison above in question form. Every one is computed from the same 29 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-04. Nothing here is estimated, and none of it is a recommendation.

Is the Health Information Services sector outperforming S&P 500?

Health Information Services has underperformed S&P 500 by 9.3% over 52 weeks and 8.3% over 13 weeks. 12 of 29 covered companies beat the S&P 500 on Mansfield relative strength, while 12 of 29 beat the sector itself.

Which Health Information Services company is largest by revenue?

Veeva Systems Inc. leads with revenue of $3,319 million, based on 22 of 29 comparable companies through Jun 2026.

Which Health Information Services company is growing fastest?

Carlsmed, Inc. has the fastest current revenue growth at 75%, across 22 of 29 comparable companies.

Which Health Information Services company has the strongest 4-Factor Sector Score?

HealthEquity, Inc. ranks first at 67.9/100 with 85.3% evidence confidence. The score prioritizes research; it is not a buy recommendation.

Which Health Information Services company has the lowest comparable PEG?

Veeva Systems Inc. has the lowest comparable PEG at 1.47, among 6 of 29 companies whose earnings and growth are steady enough for the ratio to mean anything.

How much history does this Health Information Services comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

Which Health Information Services company is the biggest?

Veeva Systems Inc. is the largest, with trailing-twelve-month revenue of $3,319 million, ahead of Privia Health Group, Inc. at $2,246 million. That covers 22 of 29 companies with comparable reporting through Jun 2026.

Which Health Information Services company has the best profit margins?

Veeva Systems Inc. has the highest operating margin at 30.9%, from 29 of 29 comparable companies. 10x Genomics, Inc. shows the biggest recent improvement, at +14.1 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

Which Health Information Services company makes the most profit?

Veeva Systems Inc. earns the most, at $941 million of trailing-twelve-month net profit, from 22 of 29 comparable companies. HealthEquity, Inc. has the fastest profit growth at 89.3%, though growth off a small or recovering profit base overstates how much has actually changed.

Which Health Information Services company earns the highest return on capital?

Hinge Health, Inc. leads on return on capital employed at 8.4%, across 29 of 29 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

Which Health Information Services stock is the cheapest?

On PEG — where a LOWER number is cheaper — Veeva Systems Inc. screens cheapest at 1.47×. Only 6 of 29 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

Is the Health Information Services sector beating the market?

Health Information Services has underperformed S&P 500 by 9.3% over the last 52 weeks and 8.3% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 12 of 29 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which Health Information Services stock has the strongest price momentum?

10x Genomics, Inc. has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

Which Health Information Services company scores highest for research priority?

HealthEquity, Inc. scores 67.9 out of 100 with 85.3% evidence confidence, from 23.6 points on growth and earnings, 15.5 on capital efficiency, 12.4 on valuation and 16.4 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

How many Health Information Services companies does this comparison cover, and over what period?

It compares 29 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

What is the total market cap of the Health Information Services sector?

The 29 Health Information Services companies on this page carry $104,843 million of combined market value. Veeva Systems Inc. is the largest at $34,415 million, about 33% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-04.

What is the Health Information Services sector's P/E ratio?

The median price-to-earnings ratio across the 29 Health Information Services companies on this page is 49.4×, measured on the 18 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-04.

How is the Health Information Services sector performing?

12 of the 29 covered Health Information Services companies are beating S&P 500 on Mansfield relative strength. The sector itself is 9.3% behind S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-04.

How many Health Information Services stocks are listed in the US?

This comparison covers 29 listed Health Information Services companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Jun 2026. Membership is the full industry list — nothing is dropped for having thin data.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI